

## Vasodilators for Raynaud's Phenomenon

Kevin Su and Katie LeBlanc for Evidently Cochrane – 22<sup>nd</sup> October 2021

### References

- 1) Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD002069. DOI: 10.1002/14651858.CD002069.pub5. Accessed 06 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full>
- 2) Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, Tugwell P, Pope J. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No.: CD000467. DOI: 10.1002/14651858.CD000467.pub2. Accessed 06 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000467.pub2/full>
- 3) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. Accessed 06 October 2021. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006687.pub4>